IBDEI1ZC ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,1292,0)
 ;;=KNEE^10^121
 ;;^UTILITY(U,$J,358.4,1293,0)
 ;;=TIBIA/FIBULA^19^121
 ;;^UTILITY(U,$J,358.4,1294,0)
 ;;=ANKLE^2^121
 ;;^UTILITY(U,$J,358.4,1295,0)
 ;;=FOOT/TOE^6^121
 ;;^UTILITY(U,$J,358.4,1296,0)
 ;;=PAIN^13^121
 ;;^UTILITY(U,$J,358.4,1297,0)
 ;;=OTHER^12^121
 ;;^UTILITY(U,$J,358.4,1298,0)
 ;;=AMPUTATION STATUS^1^121
 ;;^UTILITY(U,$J,358.4,1299,0)
 ;;=SECONDARY DX ONLY^3^122
 ;;^UTILITY(U,$J,358.4,1300,0)
 ;;=FOLLOW-UP DIAGNOSIS^2^122
 ;;^UTILITY(U,$J,358.4,1301,0)
 ;;=SUTURES/DRESSINGS^1^122
 ;;^UTILITY(U,$J,358.4,1302,0)
 ;;=ESTABLISHED PATIENT^1^123
 ;;^UTILITY(U,$J,358.4,1303,0)
 ;;=CONSULTATION-CLINICIAN^2^123
 ;;^UTILITY(U,$J,358.4,1304,0)
 ;;=NEW PATIENT^3^123
 ;;^UTILITY(U,$J,358.4,1305,0)
 ;;=NEUROLYSIS^1^124
 ;;^UTILITY(U,$J,358.4,1306,0)
 ;;=NEUROSTIMULATORS^2^124
 ;;^UTILITY(U,$J,358.4,1307,0)
 ;;=OTHER PROCEDURES^3^124
 ;;^UTILITY(U,$J,358.4,1308,0)
 ;;=SPINAL PROCEDURES/NERVE BLOCKS^4^124
 ;;^UTILITY(U,$J,358.4,1309,0)
 ;;=SYMPTOMS^5^125
 ;;^UTILITY(U,$J,358.4,1310,0)
 ;;=ESTHESOPATHIES & ALLIED SYNDROMES^1^125
 ;;^UTILITY(U,$J,358.4,1311,0)
 ;;=HEADACHE^2^125
 ;;^UTILITY(U,$J,358.4,1312,0)
 ;;=SPINAL CONDITIONS^4^125
 ;;^UTILITY(U,$J,358.4,1313,0)
 ;;=PAIN^3^125
 ;;^UTILITY(U,$J,358.4,1314,0)
 ;;=INPT H&P-NEW ADMISSION^4^126
 ;;^UTILITY(U,$J,358.4,1315,0)
 ;;=INITIAL OBSERVATION^1^126
 ;;^UTILITY(U,$J,358.4,1316,0)
 ;;=INPT CONSULTATIONS^5^126
 ;;^UTILITY(U,$J,358.4,1317,0)
 ;;=INPT-ESTABLISHED PATIENT CARE^6^126
 ;;^UTILITY(U,$J,358.4,1318,0)
 ;;=INPT DISCHARGES^7^126
 ;;^UTILITY(U,$J,358.4,1319,0)
 ;;=SUBSEQUENT OBSERVATION^2^126
 ;;^UTILITY(U,$J,358.4,1320,0)
 ;;=OBSERVATION DISCHARGE^3^126
 ;;^UTILITY(U,$J,358.4,1321,0)
 ;;=INJECTIONS/DRUGS^4^127
 ;;^UTILITY(U,$J,358.4,1322,0)
 ;;=WOUND CARE^8^127
 ;;^UTILITY(U,$J,358.4,1323,0)
 ;;=MD PROCEDURES^1^127
 ;;^UTILITY(U,$J,358.4,1324,0)
 ;;=MUSCLE NERVE TESTS^5^127
 ;;^UTILITY(U,$J,358.4,1325,0)
 ;;=TEAM CONFERENCE^7^127
 ;;^UTILITY(U,$J,358.4,1326,0)
 ;;=ACUPUNCTURE^2^127
 ;;^UTILITY(U,$J,358.4,1327,0)
 ;;=CHEMODENERVATION^3^127
 ;;^UTILITY(U,$J,358.4,1328,0)
 ;;=OTHER^6^127
 ;;^UTILITY(U,$J,358.4,1329,0)
 ;;=INITIAL EVAL FOR TBI^1^128
 ;;^UTILITY(U,$J,358.4,1330,0)
 ;;=V CODES ^21^129
 ;;^UTILITY(U,$J,358.4,1331,0)
 ;;=AMPUTATION STATUS^1^129
 ;;^UTILITY(U,$J,358.4,1332,0)
 ;;=BRAIN DISORDERS^5^129
 ;;^UTILITY(U,$J,358.4,1333,0)
 ;;=CARDIOPULMONARY^6^129
 ;;^UTILITY(U,$J,358.4,1334,0)
 ;;=COMPLICATION DUE TO^8^129
 ;;^UTILITY(U,$J,358.4,1335,0)
 ;;=FRACTURES-LATE EFFECTS^10^129
 ;;^UTILITY(U,$J,358.4,1336,0)
 ;;=MENTAL DISORDERS^13^129
 ;;^UTILITY(U,$J,358.4,1337,0)
 ;;=MUSCULOSKELETAL/CONNECTIVE TISSUE^14^129
 ;;^UTILITY(U,$J,358.4,1338,0)
 ;;=LATE EFFECTS OF INJURY^12^129
 ;;^UTILITY(U,$J,358.4,1339,0)
 ;;=LATE EFFECTS OF CVA^11^129
 ;;^UTILITY(U,$J,358.4,1340,0)
 ;;=PHYSICAL CHANGES^16^129
 ;;^UTILITY(U,$J,358.4,1341,0)
 ;;=SPEECH AND LANGUAGE^19^129
 ;;^UTILITY(U,$J,358.4,1342,0)
 ;;=AUDITORY^2^129
 ;;^UTILITY(U,$J,358.4,1343,0)
 ;;=COGNITION^7^129
 ;;^UTILITY(U,$J,358.4,1344,0)
 ;;=PSYCHIATRIC-PSYCHOSOC-EMOTIONAL^18^129
 ;;^UTILITY(U,$J,358.4,1345,0)
 ;;=BACK DIAGNOSIS^3^129
 ;;^UTILITY(U,$J,358.4,1346,0)
 ;;=EXTREMITY DIAGNOSIS^9^129
 ;;^UTILITY(U,$J,358.4,1347,0)
 ;;=POST JOINT REPLACEMENT^17^129
 ;;^UTILITY(U,$J,358.4,1348,0)
 ;;=OTHER^15^129
 ;;^UTILITY(U,$J,358.4,1349,0)
 ;;=BLINDNESS^4^129
 ;;^UTILITY(U,$J,358.4,1350,0)
 ;;=SPINAL CORD INJURY^20^129
 ;;^UTILITY(U,$J,358.4,1351,0)
 ;;=EST PATIENT^1^130
 ;;^UTILITY(U,$J,358.4,1352,0)
 ;;=NEW PATIENT^2^130
 ;;^UTILITY(U,$J,358.4,1353,0)
 ;;=CONSULTATION^3^130
